Study summary
Trontinemab cleared amyloid quickly in an early trial
91%fell below the amyloid-positive threshold after 28 weeks
What was tested
Trontinemab, an antibody engineered to cross into the brain more easily, in people with early Alzheimer's.
What they found
- 49 of 54 people (91%) dropped below the threshold for amyloid on PET scans after 28 weeks.
- One-year extension data in 2026 showed the reduction held.
- This measures amyloid removal, not memory or function.
What it means
Two phase 3 trials with more than 2,000 people will show whether faster clearing means better outcomes or fewer side effects.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.